Natera, Inc. (NASDAQ:NTRA) CFO Sells $94,465.88 in Stock

Natera, Inc. (NASDAQ:NTRA – Get Rating) CFO Michael Burkes Brophy sold 2,273 shares of Natera stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $94,465.88. Following the completion of the transaction, the chief financial officer now directly owns 103,023 shares in the company, valued at $4,281,635.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, January 3rd, Michael Burkes Brophy sold 3,644 shares of Natera stock. The shares were sold at an average price of $39.55, for a total transaction of $144,120.20.
• On Wednesday, December 28th, Michael Burkes Brophy sold 915 shares of Natera stock. The shares were sold at an average price of $39.84, for a total transaction of $36,453.60.
• On Friday, December 23rd, Michael Burkes Brophy sold 429 shares of Natera stock. The shares were sold at an average price of $42.30, for a total transaction of $18,146.70.

Natera Trading Down 0.7 %

Shares of NASDAQ:NTRA traded down $0.29 during mid-day trading on Tuesday, reaching $42.94. 1,481,794 shares of the company’s stock were exchanged, compared to its average volume of 1,579,353. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of -7.56 and a beta of 1.28. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.95 and a current ratio of 3.10. Natera, Inc. has a twelve month low of $26.10 and a twelve month high of $74.82. The business’s fifty day moving average price is $39.55 and its 200-day moving average price is $44.06.

Natera (NASDAQ:NTRA – Get Rating) last released its earnings results on Tuesday, November 8th. The medical research company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.17. The business had revenue of $210.64 million for the quarter, compared to analyst estimates of $208.31 million. Natera had a negative net margin of 70.34% and a negative return on equity of 109.07%. On average, research analysts predict that Natera, Inc. will post -5.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Ronald Blue Trust Inc. acquired a new position in Natera in the second quarter valued at $26,000. Parallel Advisors LLC increased its stake in Natera by 84.2% in the second quarter. Parallel Advisors LLC now owns 829 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 379 shares in the last quarter. Assetmark Inc. increased its stake in Natera by 93.6% in the second quarter. Assetmark Inc. now owns 873 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 422 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Natera by 4,595.2% in the second quarter. Quadrant Capital Group LLC now owns 986 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 965 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in Natera by 970.2% in the third quarter. First Horizon Advisors Inc. now owns 1,006 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 912 shares in the last quarter. Institutional investors and hedge funds own 93.81% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NTRA. BTIG Research cut their target price on shares of Natera from $95.00 to $75.00 in a research report on Wednesday, November 9th. StockNews.com began coverage on shares of Natera in a research report on Wednesday, October 12th. They issued a “sell” rating on the stock. Piper Sandler restated an “overweight” rating and issued a $70.00 target price on shares of Natera in a research report on Tuesday, January 17th. Credit Suisse Group cut their target price on shares of Natera from $70.00 to $55.00 and set an “outperform” rating on the stock in a research report on Monday, November 14th. Finally, Robert W. Baird cut their target price on shares of Natera from $72.00 to $65.00 in a research report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.